This federal Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under CFDA program 93.859 Biomedical Research and Research Training, aims to build a better understanding of how viral pathogens hijack cellular DNA replication and repair machinery. The total award is $375,430 and runs from September 10, 2024 to July 31, 2029. The research program seeks to develop novel tools and methodologies to interrogate how viruses usurp, modify, and leverage host DNA...
This federal Project Grant award in the amount of $651,832 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how the herpes simplex virus (HSV-1) interacts with the host cell's DNA damage response (DDR) pathways and proteome to facilitate viral gene expression and replication. The multi-year project, starting on November 15, 2024 and running through October 31, 2029,...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) provides $249,000 in funding to The Trustees of the University of Pennsylvania to conduct research aimed at understanding how human papillomavirus (HPV) disrupts the DNA damage response in HPV-positive head and neck squamous cell carcinoma (HNSCC). The goal is to identify vulnerabilities that can be targeted with combination...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,051,266 to The Wistar Institute of Anatomy and Biology to investigate how Epstein-Barr virus (EBV) infection alters the host cell epigenome and contributes to the development of EBV-positive lymphomas. The research aims to identify the mechanism by which EBV's LMP1 oncoprotein activates the chromatin-associated...
This $892,050 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to elucidate the mechanisms used by viruses to modulate host chromatin dynamics and gene expression. The primary objectives are to investigate how the P26 protein from Pea Enation Mosaic Virus 2 (PEMV2) undergoes liquid-liquid phase separation to partition into the nucleolus and influence chromatin...
This $2,022,607 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the role of epigenetic regulation in establishing and maintaining latent herpes simplex virus (HSV) infections. The project aims to investigate how the histone modification H2AK119ub1 functions to repress HSV gene expression during latency and enable viral reactivation. The research will...
This $1,696,146 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify and evaluate HIV-1 vaccine strategies focused on the "apex" epitope of the HIV-1 envelope glycoprotein. The key objectives are to: 1) refine the definition of HIV-1 broadly neutralizing antibody precursors with long, tyrosine-sulfated heavy-chain CDR3 regions that can...
This $734,184 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the mechanisms regulating transcription and replication of the human parainfluenza virus type 3 (HPIV-3). The research, led by Trustees of Boston University's Medical Campus, aims to provide novel insights into how HPIV-3 polymerase complexes govern the balance between viral...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), funds research to define the role of human papillomavirus (HPV) integration structures in driving heterogeneity and treatment outcomes for HPV-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC). The total award amount is $1,743,816, with a project period from August 1, 2024 to April 30, 2029. The research aims to:...
This $131,268 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the role of nonreceptor tyrosine phosphatases PTPN1 and PTPN2 in regulating the cytolytic function of natural killer (NK) cells against HIV-infected cells. The primary goals are to: 1) assess how inhibiting these phosphatases affects NK cell activation and cytotoxicity against diverse...
This $216,736 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Northwestern University to uncover the roles of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) in regulating R-loops during human papillomavirus (HPV) replication. The central hypothesis is that DNA-PKcs activation is necessary to maintain R-loop homeostasis within HPV-positive cells. The research will apply genetic techniques to study how DNA-PKcs activation impacts the HPV lifecycle and analyze how DNA-PKcs mitigates R-loop formation on the viral and cellular genomes. This project aims to identify key functions of DNA-PKcs in HPV replication while elucidating important roles of DNA-PKcs in R-loop biology and cellular processes. The award period runs from Sep 2024 through May 2026.